ClinicalTrials.gg
RecruitingNCT03283852FORDEVUpdated Jun 5, 2024

Identifying New Genetic Causes to Development Disorders

An observational study in Disorders of Sex Development, Growth Disorders and Puberty Disorders, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2024-06-05.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

From the registry’s dates

  • Started Feb 2017; still recruiting 9 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,100
Sex
All
01

Study summary

Disorders of growth, puberty and sex development can have genetic causes. The exome analysis could detect new mutations responsible for these disorders and the frequency of these mutations in these disorders, their association with other malformations.

02

Conditions studied

  • Disorders of Sex Development
  • Growth Disorders
  • Puberty Disorders
03

In context

Disorders of Sex Development

32 studies on the registry are indexed under Disorders of Sex Development; 7 are open to participants now.

This study's planned enrollment of 1,100 is above the median of 84 across 17 observational studies indexed under Disorders of Sex Development.

Browse Disorders of Sex Development studies →

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with disorders of growth, puberty and sex development and related subjects.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • congenital growth hormone deficiency
  • puberty disorder
  • gonadal dysgenesis or anorchia
  • primary ovarian failure
  • disorder of sex development
  • subjects related to a patient with one of the above criteria

Exclusion criteria

Exclusion Criteria:

  • environmental or auto-immune cause
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Geneticblood sample

    search for genetic mutations

06

What researchers measure

Primary outcomes

  1. mutation research

    frequency of genetic mutation

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03283852
Responsible party
Sponsor
First posted
Sep 14, 2017
Start date
Feb 21, 2017
Primary completion
Feb 21, 2027 (estimated)
Completion
Feb 21, 2027 (estimated)
Last update
Jun 5, 2024

Study contacts

Amélie YAVCHITZ, MD, PHD
Contact
ayavchitz@for.paris
01 48 03 64 54
Raja Brauner, PU-PH
principal investigator · Hôpital Fondation A. de Rothschild

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion